R&G PharmaStudies Co. Ltd. A Financial Flexibility Index
R&G PharmaStudies Co. Ltd. A financial flexibility index. R&G PharmaStudies Co. Ltd. A (301333) has a Financial Flexibility Index of 0.17x as of June 2022. Free cash flow of CN¥46.22 Million (operating CF CN¥40.98 Million minus capex CN¥5.24 Million) represents 0% of total liabilities (CN¥264.39 Million). See 301333 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of R&G PharmaStudies Co. Ltd. A (2019–2025)
Financial flexibility index of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. Historical Financial Flexibility Index trend for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Check 301333 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
R&G PharmaStudies Co. Ltd. A Financial Flexibility Index by Year (2019–2025)
R&G PharmaStudies Co. Ltd. A financial flexibility index by year from 2019 to 2025. Year-by-year free cash flow to debt coverage for R&G PharmaStudies Co. Ltd. A. For the full cash flow conversion analysis, see R&G PharmaStudies Co. Ltd. A cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.31x | CN¥133.48 Million | CN¥114.20 Million | CN¥423.89 Million | ▼ -9.9% |
| 2024 | 0.35x | CN¥174.74 Million | CN¥154.76 Million | CN¥500.09 Million | ▼ -47.5% |
| 2023 | 0.67x | CN¥212.44 Million | CN¥192.56 Million | CN¥319.17 Million | ▲ +27.3% |
| 2022 | 0.52x | CN¥151.29 Million | CN¥130.47 Million | CN¥289.35 Million | ▼ -18.0% |
| 2021 | 0.64x | CN¥152.86 Million | CN¥114.57 Million | CN¥239.66 Million | ▲ +82.8% |
| 2020 | 0.35x | CN¥69.58 Million | CN¥44.10 Million | CN¥199.38 Million | ▼ -46.9% |
| 2019 | 0.66x | CN¥129.48 Million | CN¥103.48 Million | CN¥197.12 Million | — |